Evidence map›Paper›PMID 34857243›Full record

Observational studyClinical nutrition ESPEN2021

Observational study on the benefit of a nutritional supplement, supporting immune function and energy metabolism, on chronic fatigue associated with the SARS-CoV-2 post-infection progress.

Maria Sole Rossato, Elisa Brilli, Nicola Ferri, Giulio Giordano, Germano Tarantino

Registry-linked trialOpen access · hybridAbstract readObservational Study
In one paragraph

Observational study in Clinical nutrition ESPEN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06137833 (Clinical Study on Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06137833 narecruitingnot on this mapstarted 2023, after this paper: background citation

Clinical Study on Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

TypeinterventionalSponsorPharmanutra S.p.a.Ran2023 to 2025Enrolled92ConditionsFatigue, Breast CancerArmsAPPOPRTAL®, Placebo
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Article
  5. Impact of nutrition on long COVID.Sports medicine and health science · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. The Microbiota in Long COVID.International journal of molecular sciences · 2024
    Review
  15. Review
  16. Review
  17. Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Maria Sole RossatoPharmanutra S.p.a., Pisa, Italy. Electronic address: ms.rossato@pharmanutra.it.
Elisa BrilliAlesco S.r.l., Pisa, Italy.
Nicola FerriDipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padova, Italy.
Giulio GiordanoHematology Service, Internal Medicine Division, Regional Hospital "Antonio Cardarelli", Campobasso, Italy.
Germano TarantinoPharmanutra S.p.a., Pisa, Italy.
Abiogen Pharma (Italy) · ITOspedale Antonio Cardarelli · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsRecent studies have verified that the SARS-CoV-2 infection (from December 2019 has affected 123 million people throughout the world and more than 3 million people in Italy), can have medium-term and long-term effects, collectively referred to as "post-Covid syndrome" or "long-Covid" characterized by chronic fatigue, followed by muscle weakness, dyspnea and headache. Chronic fatigue or chronic tiredness is a persistent symptom both in patients who have experienced a severe infection and in those who have experienced a mild form of infection. Studies conducted on both patients discharged from hospital and patients managed at home showed that there was no association between the severity of the Coronavirus disease (Covid-19) and the subsequent chronic fatigue symptom. The aim of this study was to evaluate the ability of a nutritional supplement based on vitamins, minerals, amino acids and plant extracts (Apportal®) intake, to ameliorate the general health status in particular the chronic fatigue symptom in subjects after SARS-CoV-2 negativity.

methodsParticipants were advised to take one sachet daily of Apportal® for 28 consecutive days. At the beginning (T0), after 14 days (T1) and after 28 days (T2) of supplementation, general fatigue, mental fatigue and Quality of Life indexes were evaluated through specific questionnaires. The assessment of quality of life and health status were measured through the EuroQoL-5D questionnaire, chronic fatigue using the FACIT-Fatigue questionnaire and mental fatigue using the modified Chalder questionnaire.

results201 subjects were enrolled for the study; results showed a significant improvement in all indexes analyzed after 14 and 28 days of supplementation. The main significant improvement was observed after the first 14 days and it was further confirmed at 28 days as well. The RTE (Relative Treatment Effect) trend about quality of life, health status, FACIT-Fatigue and mental fatigue in the three questionnaires was statistically significant (Wald Statistic, p < 0.0001). The data of FACIT-questionnaire showed an improvement of at least 1 unit in 76.62% of subjects after 14 days and in 90.05% of subjects after 28 days. An improvement of 10-unit was found in about one third of subjects after 14 days and in half of the subjects after 28 days.

conclusionsThis study shows that Apportal® can reduce chronic fatigue and improve quality of life and health status in subjects after SARS-CoV-2 negativity due to the synergistic effect of its components.

Indexed as

COVID-19Fatigue Syndrome, ChronicDietary SupplementsEnergy MetabolismHumansImmunityQuality of LifeSARS-CoV-2Chronic fatigueLong-CovidNutritional supplementSARS-CoV-2

Identifiers

PMID34857243
PMCPMC8420132
OpenAlexW3198620064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.